ROCO
1784
Market cap93mUSD
Oct 08, Last price
59.30TWD
1D
-1.17%
1Q
-14.18%
Jan 2017
95.71%
IPO
-2.23%
Name
Bionet Corp
Chart & performance
P/E
58.01
P/S
2.41
EPS
1.02
Div yield, %
2.39%
Shrs. gr., 5y
-55.49%
Rev. gr., 5y
8.92%
Revenues
1.24b
+1.19%
Net income
51m
-38.56%
CFO
148m
-16.12%
Dividend
Oct 01, 20260.88096 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.
Key people
Chairman of the Board · since 2009
General Manager · since 2020
Huixin Huang
Deputy General Manager-Marketing · since 2018
Qianyu Liu
Head of Finance & Accounting · since 2023
Mingzhong Yu
Corporate Governance Officer · since 2023
Director · since 2014
Director · since 2003
Director · since 2006
Cuiru Zhang
Director · since 2016
Independent Director · since 2025
Independent Director · since 2006
Independent Director · since 2022
Zuhui Liu
Independent Director · since 2025
Independent Director
Wenxi Yan
Independent Director · since 2006
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||